Meeting
2014 ASCO Annual Meeting
Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).
Authors
Mira F. Liebman
University Health Network, University of Toronto, Toronto, ON, Canada
Mira F. Liebman , William Brien , Wendy R. Parulekar , Karen A. Gelmon , Lois E. Shepherd , Jennifer A. Ligibel , Dawn L. Hershman , Priya Rastogi , Ingrid A. Mayer , Timothy J. Hobday , Julie Lemieux , Alastair Mark Thompson , Kathleen I. Pritchard , Timothy Joseph Whelan , Som Mukherjee , Haji I. Chalchal , Vanessa Bernstein , Vuk Stambolic , Bingshu E. Chen , Pamela Jean Goodwin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01101438
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 542)
DOI
10.1200/jco.2014.32.15_suppl.542
Abstract #
542
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).
First Author: Dawn L. Hershman
Poster
2013 ASCO Annual Meeting
Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).
First Author: Pamela Jean Goodwin
Poster
2011 ASCO Annual Meeting
A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer (BC) (NCIC Clinical Trials Group MA.32).
First Author: W. Parulekar
Poster
2023 ASCO Annual Meeting
Phase 3 randomized placebo-controlled trial of donepezil for cancer-related cognitive impairment among breast cancer survivors: Results on patient-reported cognitive function from the Wake Forest NCI Community Oncology Research Program (NCORP) Research Base REMEMBER trial (WF97116).
First Author: Alayna E Ernster